Drug
Semaglutide Pen Injector [Ozempic]
Semaglutide Pen Injector [Ozempic] is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
17%
Ph phase_4
3
50%
Ph phase_1
1
17%
Ph phase_2
1
17%
Phase Distribution
1
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
3(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(3)
Completed(1)
Other(2)
Detailed Status
Recruiting2
unknown2
Not yet recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 43 (50.0%)
Trials by Status
recruiting233%
not_yet_recruiting117%
unknown233%
completed117%
Recent Activity
2 active trials
Showing 5 of 6
recruitingphase_1
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
recruitingphase_4
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
NCT04873050
not_yet_recruitingphase_2
Semaglutide in Auto-HSCT
NCT06449625
unknownphase_3
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
NCT05950516
completedphase_4
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
NCT05857085
Clinical Trials (6)
Showing 6 of 6 trials
NCT05071898Phase 1
Pharmacogenetics of Response to GLP1R Agonists
NCT04873050Phase 4
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
NCT06449625Phase 2
Semaglutide in Auto-HSCT
NCT05950516Phase 3
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
NCT05857085Phase 4
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
NCT05606471Phase 4
Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6